智通财经APP讯，恒瑞医药(01276)发布公告，于2026年1月30日，该公司斥资人民币1995.99万元回购 34.31万股A股股份，每股回购价人民币58.12-58.21元。 ...

Group 1 - The top three companies with the highest AH premium rates are Northeast Electric (00042) at 831.03%, Zhejiang Shibao (01057) at 339.32%, and Sinopec Oilfield Service (01033) at 323.71% [1][2] - The bottom three companies with the lowest AH premium rates are CATL (03750) at -14.62%, China Merchants Bank (03968) at -3.22%, and Hengrui Medicine (01276) at 1.77% [1][2] - Sinopec Oilfield Service (01033), Andeli Juice (02218), and Shandong Molong (00568) have the highest deviation values at 53.41%, 21.68%, and 19.01% respectively [1][2] Group 2 - The companies with the lowest deviation values include Zhejiang Shibao (01057) at -58.91%, Yangtze Optical Fibre and Cable (06869) at -49.00%, and Fudan Zhangjiang (01349) at -24.81% [1][2][4] - The top ten AH stocks by premium rate include companies like Hongye Futures (03678) and Beijing Electromechanical (00187) with premium rates of 258.91% and 257.99% respectively [2] - The bottom ten AH stocks by premium rate include Weichai Power (02338) and Midea Group (00300) with premium rates of 6.84% and 8.51% respectively [2]

FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 公司名稱： 江蘇恒瑞醫藥股份有限公司 呈交日期： 2026年1月30日 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 A | | 於香港聯交所上市 | 否 | | | 證券代號 (如上市) | 600276 | 說明 | A股（於上海證券交易所上市） | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | 已發行股份（不包括庫存股份）變動 | | 庫存股份變動 | | | | | 事件 | 已發行股份（不包括庫存股份）數 目 | 佔有關事件 ...

Group 1 - Approval Status: Subsidiary Shandong Shengdi Pharmaceutical received the "Drug Clinical Trial Approval Notice" for HRS-7535, approved to conduct Phase III clinical trials for the treatment of chronic kidney disease [1][2] - Drug Characteristics: A novel oral small molecule GLP-1R agonist, with no similar oral drugs available globally. Mechanism of action includes promoting insulin secretion, lowering glucagon levels, inhibiting gastric emptying, and enhancing satiety. Preclinical data shows significant improvement in chronic kidney disease symptoms in animals [1][2] - R&D Investment: Cumulative R&D investment to date is approximately 369 million yuan (unaudited) [1][2]

Core Viewpoint - Heng Rui Medicine has received approval from the National Medical Products Administration for clinical trials of HRS-7535, a novel oral small molecule GLP-1 receptor agonist, which shows promise in treating chronic kidney disease and obesity-related conditions [1] Group 1: Product Development - HRS-7535 is designed to activate GLP-1 receptors, promoting insulin secretion and reducing glucagon secretion while also suppressing gastric emptying [1] - The drug has shown significant improvement in preclinical models of chronic kidney disease (CKD) [1] - The total research and development investment for HRS-7535 has reached approximately 36.94 million yuan (unaudited) [1] Group 2: Market Context - There are currently no oral small molecule GLP-1 receptor agonists available in the global market [1]

Core Viewpoint - Heng Rui Medicine (01276) announced that its subsidiary, Shandong Shengdi Pharmaceutical Co., Ltd., received approval from the National Medical Products Administration (NMPA) to conduct clinical trials for HRS-7535 tablets, a novel oral small molecule GLP-1 receptor agonist [1] Group 1: Product Development - HRS-7535 tablets are designed to activate human GLP-1 receptors, promoting insulin secretion from the pancreas, reducing glucagon secretion, and inhibiting gastric emptying [1] - The drug also enhances satiety and suppresses appetite through central nervous system effects, leading to a direct reduction in energy intake [1] - Preclinical data indicates that HRS-7535 can significantly improve symptoms of chronic kidney disease (CKD) in animal models [1] Group 2: Market Context - There are currently no oral small molecule GLP-1 receptor agonists available in the global market [1] - The total research and development investment for the HRS-7535 project has reached approximately 369.4 million yuan (unaudited) [1]

Core Viewpoint - Heng Rui Medicine's subsidiary, Shandong Shengdi Pharmaceutical, has received approval from the National Medical Products Administration for the clinical trial of HRS-7535 tablets, which will be used to treat chronic kidney disease [1]. Group 1: Drug Information - Drug Name: HRS-7535 tablets [1] - Dosage Form: Tablet [1] - Application Matter: Clinical trial [1] - Acceptance Numbers: CXHL2501214, CXHL2501215, CXHL2501216 [1] Group 2: Approval Details - Approval Conclusion: HRS-7535 tablets meet the requirements for drug registration and are allowed to proceed with Phase III clinical trials [1] - Application Indication: Intended for the treatment of chronic kidney disease [1] - Acceptance Date: November 5, 2025 [1]

Core Viewpoint - Heng Rui Medicine (01276) has received a notice from the National Medical Products Administration regarding the acceptance of its application for the marketing license of the innovative drug injection of Camrelizumab combined with Apatinib for a new indication [1] Group 1: Clinical Trial Details - The application for the new indication is based on a randomized, controlled, open-label, multicenter Phase III clinical trial (SHR-1210-III-336 study) evaluating the efficacy and safety of Camrelizumab and Apatinib combined with TACE compared to TACE alone in patients with unresectable hepatocellular carcinoma [1] - The study was led by Academician Fan Jia and Professor Qin Shukui from Zhongshan Hospital, Fudan University, with participation from 34 centers nationwide, enrolling a total of 423 patients [1] Group 2: Study Outcomes - The primary efficacy endpoint was progression-free survival (PFS) assessed by a blinded independent radiological review committee (BIRC); secondary endpoints included overall survival (OS), investigator-assessed PFS, BIRC and investigator-assessed objective response rate (ORR), disease control rate (DCR), and duration of response (DoR) [1] - Interim analysis results indicated that the PFS assessed by BIRC showed a significant clinical improvement in the Camrelizumab combined with Apatinib and TACE group compared to the TACE alone treatment, with a trend observed for OS benefit [1] - This combination therapy is expected to become a new clinical treatment option for patients with unresectable hepatocellular carcinoma [1]

Core Viewpoint - Heng Rui Medicine (01276.HK) has received a notice from the National Medical Products Administration regarding the acceptance of its new indication application for the innovative drug injection of Carrelizumab combined with Apatinib Mesylate tablets [1] Group 1 - The company and its subsidiary, Suzhou Shengdiya Biopharmaceutical Co., Ltd., have successfully submitted a listing application for a new indication [1]

Jiangsu Hengrui Pharmaceuticals Co., Ltd. 江蘇恒瑞醫藥股份有限公司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：1276） 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部分內容所產生或因依賴 該等內容而引致的任何損失承擔任何責任。 海外監管公告 本公告乃根據香港聯合交易所有限公司證券上市規則第13.10B條刊發。 根據中華人民共和國的有關法例規定，江蘇恒瑞醫藥股份有限公司（「本公司」）在 上海證券交易所網站( www.sse.com.cn )刊發了以下公告。茲載列如下，僅供參閱。 承董事會命 江蘇恒瑞醫藥股份有限公司 董事長 孫飄揚先生 中國上海 2026年1月29日 於本公告日期，董事會成員包括(i)執行董事孫飄揚先生、戴洪斌先生、馮佶女 士、張連山先生、江寧軍先生及孫杰平先生；(ii)非執行董事郭叢照女士；及(iii) 獨立非執行董事董家鴻先生、曾慶生先生、孫金雲先生及周紀恩先生。 近日，江苏恒瑞医药股份有限公司（以下简称"公司"）子公司山东盛迪医 药有 ...